Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis
-
Published:2023-12
Issue:
Volume:
Page:
-
ISSN:0190-9622
-
Container-title:Journal of the American Academy of Dermatology
-
language:en
-
Short-container-title:Journal of the American Academy of Dermatology
Author:
Blauvelt AndrewORCID,
Rich Phoebe,
Sofen Howard,
Strober Bruce,
Merola Joseph F.,
Lebwohl Mark,
Morita Akimichi,
Szepietowski Jacek C.,
Lambert Jo,
Hippeli Lauren,
Colston Elizabeth,
Balagula Eugene,
Banerjee Subhashis,
Thaçi Diamant
Funder
Bristol-Myers Squibb
Reference21 articles.
1. Management of difficult to treat locations of psoriasis. Scalp, face, flexures, palm/soles and nails;Kragballe;Curr Probl Dermatol,2009
2. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation;Chan;J Am Acad Dermatol,2009
3. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2);Rich;J Am Acad Dermatol,2016
4. Scalp psoriasis: a review of current topical treatment options;Papp;J Eur Acad Dermatol Venereol,2007
5. Long-term management of scalp psoriasis: perspectives from the International Psoriasis Council;Kragballe;J Dermatolog Treat,2013
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献